NGARi · Sovereign bioprocessing
Bring the model to the process.
In regenerative medicine the manufacturing process is the intellectual property — the decellularization parameters, the enzyme concentrations, the handling that produces consistent bioactivity. Sending that to a cloud QMS or a cloud ML platform weakens the trade-secret position it depends on. So we don't. The compute arrives, the process data stays, and the record of what was done leaves with a signature on it.
On-premises · air-gapped by default · no trained model and no weights · no measured outcomes claimed
The trade secret is the process
Trade-secret protection depends on taking reasonable measures to keep the information secret. A cloud quality system, a cloud ML pipeline or a vendor's inference endpoint all put the process data on somebody else's server — and a security questionnaire will ask exactly that question. For a company whose entire advantage is a manufacturing method, the architecture is the argument.
Process data
Temperature, pH, pressure, flow rate, enzyme concentration and perfusion time — the parameter space that produces the material. Recorded and analysed locally, never uploaded.
Assay data
Residual DNA, glycosaminoglycan retention, collagen, elastin and cytocompatibility — the markers that decide whether a lot is releasable.
Records
What a regulator or an auditor will ask for: who did it, when, from what source, and whether the record can still be trusted months later.
What the engine does
Four things, all deterministic, all readable by a process engineer without trusting a model. Every one of them runs on the appliance, on the lab network.
Parameter ↔ marker correlation
Ranks every process parameter against every assay marker. A parameter that never varied returns an undefined coefficient, not zero — "no information" and "no relationship" are different findings, and conflating them is how a held setpoint gets mistaken for a proven non-factor.
Window drift
Compares a baseline window to the recent runs and reports the parameters that moved. Catches an excursion that drives no marker at all — the kind a purely correlational approach misses by construction.
Release-policy evaluation
Evaluates every run and lot against a versioned, declared specification: marker limits, validated parameter windows, and worst-case roll-up to lot. This is spec evaluation, not prediction, and it says so in its own return value.
Record-integrity gap report
Checks the records against a 21 CFR Part 11 and ALCOA+ shaped checklist — attribution, contemporaneity, provenance, completeness, plausibility, consistency — and reports the gaps it can see. Notably, it reports its own missing controls rather than assuming them.
The honest line
There is no trained model and no weights in this engine today, and it has never seen a partner's data. It is a deterministic reference implementation of the analysis loop. A predictive bioactivity model needs a labelled dataset, a held-out split and a measured error — none of which exists yet, and pretending otherwise would be the fastest way to lose a scientific founder's trust.
What ships, and what is an engagement
| Layer | Status |
|---|---|
| Appliance, air-gap mode, hash-chained audit, signed attestations | Shipping |
| Correlation, drift, release-policy evaluation, record-integrity report | Working reference implementation, synthetic fixture |
| Read-only connectors for a decellularization system and an assay store | Reference adapters; no tenant has ever been contacted |
| Trained bioactivity model | Does not exist |
| Measured process-development or submission speed-up | Not measured |
| 21 CFR Part 11 system validation | Not performed |
| Deployment on a customer site | Engagement |
Where it fits
Build it in, don't retrofit
A process being automated now is the cheapest possible moment to instrument it. Every run from the first one becomes evidence; retrofitting means reconstructing history that was never captured.
Records that survive inspection
An audit trail that is hash-chained and verifiable is a different object from a log file. It is what makes a record worth something months later.
Nothing to migrate later
The appliance is bought once and lives on the lab network. There is no per-seat licence, no per-inference bill and no vendor endpoint holding the process know-how.
What we are not claiming
- No trained model, no weights, no measured prediction accuracy of any kind.
- No measured reduction in process-development time or regulatory-preparation time.
- No regulatory approval, no certification, and no system validation. The record check is a gap report against a named checklist — not a compliance determination and not legal advice.
- No live customer deployment, no connected decellularization system, and no assay tenant.
- No claim that any of this is FDA-ready. Building for a regulated pathway means naming the regulation (21 CFR Part 11, ALCOA+) and doing the validation work — not skipping it.
Tell us what your process measures.
If your competitive advantage is a manufacturing method, the architecture question comes before the model question. We are happy to start there.